Potential For Obesity Drugs To Lower Medicare Costs Justifies Policy Change, Vivus Study Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The study argues that covering prescription obesity drugs could reduce Medicare spending by $6,000 to $13,000 per patient over 10 years, which should justify allowing the Part D drug program to pay for the drugs, which it currently does not.